How to Evaluate Prospective Diagnostic Laboratory Partners for Your Patient Support Program

Why It Matters

Effective diagnostic partners translate PSP investments into measurable adherence gains and safety outcomes, directly influencing drug uptake and market success. Selecting the right lab partner therefore becomes a strategic lever for pharmaceutical companies seeking faster patient access and stronger therapy adoption.

Key Takeaways

• $5B annual spend on patient support programs worldwide.
• Lab data improves adherence, safety, and provider confidence.
• Partner criteria: location access, personalized design, caring culture.
• Rapid turnaround and integrated reporting accelerate treatment decisions.
• LifeLabs exemplifies end‑to‑end PSP diagnostic partnership.

Pulse Analysis

Patient support programs have evolved from peripheral services to core revenue drivers for pharma, with more than $5 billion poured into them each year. While financial assistance and education are visible components, the hidden engine behind successful PSPs is diagnostic testing. Rapid, accurate lab results enable clinicians to fine‑tune dosing, catch adverse events early, and personalize adherence interventions, thereby turning program participation into tangible clinical benefits and cost savings.

Choosing a diagnostic partner is no longer a logistical afterthought. Sponsors must prioritize a network that offers widespread, convenient collection sites so patients can complete tests without disrupting their treatment schedule. Equally critical is the partner’s ability to tailor workflows to specific therapies and disease states, providing custom reporting dashboards and real‑time alerts that align with the sponsor’s outcomes goals. Finally, an organizational culture rooted in patient empathy ensures that every touchpoint—from sample collection to result communication—reinforces the therapeutic relationship and sustains long‑term engagement.

LifeLabs illustrates how these principles converge in practice. With over 380 patient service centers across Canada, rapid courier pickups at infusion sites, and a 24/7 support model, the company delivers end‑to‑end services that extend beyond pure diagnostics to include digital outreach, marketing collateral, and provider education. For drug developers, partnering with such a comprehensive lab not only streamlines operational complexity but also accelerates market access, improves real‑world evidence collection, and ultimately drives higher therapy adoption rates.